Concepedia
Statistics
Publications
36
Citations
2.1K
H-Index
22
Active since
1981
Affiliations
Eli Lilly (United States)(Current)
Halozyme Therapeutics (United States)
Alkermes (United States)
Profil Institute for Clinical Research
Precision Research Institute
Douglas B. Muchmore is an author at Eli Lilly (United States) specializing in medicine, diabetes mellitus, and pharmacology.
Publications per year
1981–2023
Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial
Jane A. Cauley, Larry Norton, Marc E. Lippman et al. · Breast Cancer Research and Treatment · 2001 · 681 citations
Medicine, Oncology, Pharmacotherapy +10
A Comparison of the Effects of Raloxifene and Estrogen on Bone in Postmenopausal Women1
Karen M. Prestwood, M. Gunness, Douglas B. Muchmore et al. · The Journal of Clinical Endocrinology & Metabolism · 2000 · 139 citations · Full text
Medicine, Endocrinology, Pharmacotherapy +17
Glimepiride, a New Once-Daily Sulfonylurea: A double-blind placebo-controlled study of NIDDM patients
Julio Rosenstock, Ellis Samols, Douglas B. Muchmore et al. · Diabetes Care · 1996 · 131 citations
Medicine, Pharmacology, Pharmacotherapy +15
Self-monitoring of blood glucose in overweight type 2 diabetic patients
Douglas B. Muchmore, Jane A. Springer, Michael Miller · Acta Diabetologica · 1994 · 113 citations
Medicine, Endocrinology, Internal Medicine +13
Effect of raloxifene on breast cancer cell Ki67 and apoptosis: a double-blind, placebo-controlled, randomized clinical trial in postmenopausal patients.
Mitch Dowsett, N.J. Bundred, Andrea DeCensi et al. · PubMed · 2001 · 108 citations
Medicine, Oncology, Pharmacology +17
1–5 of 36